Literature DB >> 16869769

Epigenetic changes in cancer and preneoplasia.

J G Herman1.   

Abstract

Recent studies have identified an increasing number of genes that are inactivated by promoter region methylation in cancer. Some of these genes were initially identified as altered genetically in cancer, but in other tumors they are silenced in association with promoter region CpG island methylation. New approaches for screening the genome add to this list of candidate tumor suppressor genes, and many genes regulated key pathways in cancer, including cell cycle control, DNA repair, and apoptosis. Transcription factors may also be silenced by promoter region methylation, affecting the expression of many downstream target genes and globally altering the cancer phenotype. Determining loss of expression is important in assigning functional importance to promoter region methylation for any gene. Individual cancers have alterations in many different genes, affecting many of these important pathways and contributing to the cancer phenotype. The number of genes targeted for promoter region methylation increases during neoplastic progression. These studies suggest that the epigenetic change of promoter region methylation plays a critical role in neoplastic transformation and progression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16869769     DOI: 10.1101/sqb.2005.70.036

Source DB:  PubMed          Journal:  Cold Spring Harb Symp Quant Biol        ISSN: 0091-7451


  13 in total

1.  Qualitative and quantitative promoter hypermethylation patterns of the P16, TSHR, RASSF1A and RARβ2 genes in papillary thyroid carcinoma.

Authors:  Javad Mohammadi-asl; Bagher Larijani; Zhamak Khorgami; Seyed Mohammad Tavangar; Vahid Haghpanah; Majid Kheirollahi; Parvin Mehdipour
Journal:  Med Oncol       Date:  2010-06-10       Impact factor: 3.064

2.  Differences in Genome-wide DNA Methylation Profiles in Breast Milk by Race and Lactation Duration.

Authors:  Brittny C Davis Lynn; Clara Bodelon; Ruth M Pfeiffer; Hannah P Yang; Howard H Yang; Maxwell Lee; Peter W Laird; Mihaela Campan; Daniel J Weisenberger; Jeanne Murphy; Joshua N Sampson; Eva P Browne; Douglas L Anderton; Mark E Sherman; Kathleen F Arcaro; Gretchen L Gierach
Journal:  Cancer Prev Res (Phila)       Date:  2019-09-03

3.  Racial variation in breast tumor promoter methylation in the Carolina Breast Cancer Study.

Authors:  Kathleen Conway; Sharon N Edmiston; Chiu-Kit Tse; Christopher Bryant; Pei Fen Kuan; Brionna Y Hair; Eloise A Parrish; Ryan May; Theresa Swift-Scanlan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-03-25       Impact factor: 4.254

4.  SGI-110: DNA Methyltransferase Inhibitor Oncolytic.

Authors:  E A Griffiths; G Choy; S Redkar; P Taverna; M Azab; A R Karpf
Journal:  Drugs Future       Date:  2013-08       Impact factor: 0.148

5.  Development of sporadic microsatellite instability in colorectal tumors involves hypermethylation at methylated-in-tumor loci in adenoma.

Authors:  Michiel F G de Maat; Norihiko Narita; Anne Benard; Tetsunori Yoshimura; Christine Kuo; Rob A E M Tollenaar; Noel F C C de Miranda; Roderick R Turner; Cornelis J H van de Velde; Hans Morreau; Dave S B Hoon
Journal:  Am J Pathol       Date:  2010-10-15       Impact factor: 4.307

6.  Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma.

Authors:  Diego F Calvisi; Sara Ladu; Alexis Gorden; Miriam Farina; Ju-Seog Lee; Elizabeth A Conner; Insa Schroeder; Valentina M Factor; Snorri S Thorgeirsson
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

7.  HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D signaling.

Authors:  Cassandra A Godman; Rashmi Joshi; Brendan R Tierney; Emily Greenspan; Theodore P Rasmussen; Hsin-Wei Wang; Dong-Guk Shin; Daniel W Rosenberg; Charles Giardina
Journal:  Cancer Biol Ther       Date:  2008-10-07       Impact factor: 4.742

8.  Epigenetics and epigenetic alterations in pancreatic cancer.

Authors:  Noriyuki Omura; Michael Goggins
Journal:  Int J Clin Exp Pathol       Date:  2008-11-15

9.  Hypomethylation of intragenic LINE-1 represses transcription in cancer cells through AGO2.

Authors:  Chatchawit Aporntewan; Chureerat Phokaew; Jittima Piriyapongsa; Chumpol Ngamphiw; Chupong Ittiwut; Sissades Tongsima; Apiwat Mutirangura
Journal:  PLoS One       Date:  2011-03-15       Impact factor: 3.240

10.  Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma.

Authors:  Kinga A Kocemba; Richard W J Groen; Harmen van Andel; Marie José Kersten; Karène Mahtouk; Marcel Spaargaren; Steven T Pals
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.